Can Molecular Response Help Predict Clinical Outcome for TKI Treatment in Lung Cancer?
Time: 4:35 pm
day: Day One
• Model: Lung cancer, Phase 3 study, with comparator arm, and treatment with tyrosine kinase inhibitors
• 3 approaches utilized to examine molecular response either via difference from baseline or via ratio to baseline with arbitrary cut off, and various ways to integrate variant calls from ctDNA
• Correlation with clinical outcome (OR and PFS)
• In one case there is good correlation between molecular response and clinical outcome and in the other not so much